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Introduction: Our objective was to assess the capacity of dendrimer aza-bis-phosphonate (ABP) to modulate
phenotype of monocytes (Mo) and monocytes derived dendritic cells (MoDC) activated in response to toll-like
receptor 4 (TLR4) and interferon γ (IFN- γ) stimulation.
Methods: Mo (n = 12) and MoDC (n = 11) from peripheral blood of healthy donors were prepared. Cells were
preincubated or not for 1 hour with dendrimer ABP, then incubated with lipopolysaccharide (LPS; as a TLR4 ligand)
and (IFN-γ) for 38 hours. Secretion of tumor necrosis factor α (TNFα), interleukin (IL) -1, IL-6, IL-12, IL-10 and IL-23 in
the culture medium was measured by enzyme-linked immunosorbent assay (ELISA) and Cytokine Bead Array.
Differentiation and subsequent maturation of MoDC from nine donors in the presence of LPS were analyzed by
flow cytometry using CD80, CD86, CD83 and CD1a surface expression as markers.
Results: Mo and MoDC were orientated to a pro-inflammatory state. In activated Mo, TNFα, IL-1β and IL-23 levels
were significantly lower after prior incubation with dendrimer ABP. In activated MoDC, dendrimer ABP promoted
IL-10 secretion while decreasing dramatically the level of IL-12. TNFα and IL-6 secretion were significantly lower in
the presence of dendrimer ABP. LPS driven maturation of MoDC was impaired by dendrimer ABP treatment, as
attested by the significantly lower expression of CD80 and CD86.
Conclusion: Our data indicate that dendrimer ABP possesses immunomodulatory properties on human Mo and
MoDC, in TLR4 + IFN-γ stimulation model, by inducing M2 alternative activation of Mo and promoting tolerogenic
MoDC.Introduction
Cells from the myelo-monocytic lineage are involved in
the pathophysiology of rheumatoid arthritis (RA) [1]. Mac-
rophages and dendritic cells are thought to present arthri-
togenic peptides during the initial phase of the disease,
leading to the activation of CD4+ T lymphocytes [2]. Mac-
rophages also secrete pro-inflammatory cytokines (TNFα,
IL-1 and IL-6), which are responsible for the inflammation* Correspondence: jean-luc.davignon@inserm.fr
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rived from the monocytic lineage and participate in the
production of cytokines and chemokines in situ, thus con-
tributing to the proteolytic degradation of the cartilage [3].
In addition, osteoclasts are derived from a monocytic pre-
cursor [4].
Polarization of monocytes is a current concept derived
from that of T cell polarization. Classically, the prototyp-
ical pro-inflammatory M1 polarization is obtained by acti-
vation mediated by LPS + IFN-γ or TNFα. Conversely,
M2 polarization corresponds to a series of phenotypes ob-
tained after a so-called “alternative” activation by IL-4 or
IL-13 [5,6]. Although M1 produces IL-12, the differentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a functional point of view, M2 macrophages are involved
in immunoregulation and tissue reparation. Considering
the characteristics of M1 and M2 phenotypes with regard
to cytokine production, the IL-12:IL-10 balance has been
proposed to evaluate the polarization of macrophages in
inflammatory conditions [5].
Although their precise role in RA is not completely
understood, dendritic cells (DCs) are most important in
the initiation of the immune response. They are pro-
fessional antigen presenting cells and also secrete pro-
inflammatory cytokines, depending on the stimulation [7].
Besides their role in inflammation, tolerogenic DCs par-
ticipate in immunoregulation through the production of
indoleamine 2,3-dioxygenase (IDO), the production of IL-
10, and the regulated expression of their co-stimulatory
molecules, such as CD80 and CD86 [8]. Their role in RA
could thus be different according to the pattern of stimu-
lation in their environment.
Toll-like receptors (TLR) expressed at the surface of Mo
and DC are responsible for early, powerful and non-
specific immune reaction in response to danger signals.
They are capable of initiating adaptive immune response
as well as regulating co-stimulation, cytokine and chemo-
kine secretion [9]. A central role of TLR in the initiation
and/or maintenance of RA has been proposed. On the one
hand, TLR2 and 4 are capable of recognizing endogenous
proteins among which some are of synovial origin (Hsp60,
fibrinogen, hyaluronic acid) [10-16]. On the other hand,
TLR2 and 4 recognize infectious targets either latent or
persistent in the organism [17-22]. TLRs have the capacity
to initiate and maintain an inflammatory reaction in re-
sponse to endogenous danger signals and thus represent
good candidates for the long-term inflammation of RA
[23]. The induction of co-stimulation molecules on APC
by TLR may contribute to the initiation phase of the dis-
ease as well as to the vicious circle of inflammation follow-
ing the as yet unidentified triggering phenomenon [23].
Dendrimer ABP (aza-bis-phosphonate) is a synthetic
hyper-branched nanomolecule which belongs to the family
of phosphorus-containing dendrimers (Figure 1) [24].
Dendrimer ABP has shown promising results in the
treatment of experimental arthritis [25]. We have demon-
strated in two murine models that this dendrimer inhibits
arthritis and bone erosion by decreasing pro-inflammatory
cytokines, increasing anti-inflammatorycytokines as well
as inhibiting osteoclastogenesis [25]. Moreover, in human
cultures, dendrimer ABP has shown immunomodulatory
properties targeted to Mo leading to M2 activation [26],
amplification of IL-10 producing CD4 Tcells [26]. However,
this has not been previously tested in pro-inflammatory
conditions.
IFN-γ has been shown to prime cells for TLR4 induc-
tion of pro-inflammatory cytokines [27]. In this currentstudy, we have analyzed the potential mechanism through
which dendrimer ABP may act to modulate inflammation.
We thus have chosen to orientate Mo as well as DC to-
wards an anti-inflammatory state using dendrimer ABP
before applying a classical pro-inflammatory protocol
using TLR4 ligand LPS in the presence of IFN-γ. Pro-
inflammatory cytokines supposed to be involved in RA,
such as TNFα, IL-1β, IL-6, IL-12 and IL-23, were studied.
Anti-inflammatory cytokine IL-10 involved in regulation
of the immune response and in tolerogenic phenotype of
DC was also examined.
Materials and methods
Isolation of monocytes
Peripheral blood mononucleated cells (PBMCs) were ob-
tained from normal blood donors of the Etablissement
Français du Sang (EFS), Toulouse, France. Informed writ-
ten consent was obtained from all blood donors, and the
study protocol was approved by the INSERM-EFS ethical
committee. Briefly, CD14+ monocytes were purified
from PBMC isolated on Pancoll (Pan Biotech, Aidenbach,
Germany) by negative sorting using Dynabeads (Dynabeads
Untouched Human Monocytes, Invitrogen, Oslo, Norway).
Purity was measured by flow cytometry (FC-500 Beckman
Coulter, Brea, CA, USA) using a CD14-FITC antibody
(clone HCD14, Bio Legend, San Diego, CA, USA). Data
were analyzed using FlowJo (Tree Star). Purity was >90%.
Culture and activation of monocytes
Monocytes were cultured at 37°C, 5% CO2, 100% humidity
in RPMI-1640-Glutamax (Gibco; Paisley, UK) containing
10% fetal calf serum (FCS) (Gibco), penicillin (100 U/ml;
Gibco), streptomycin (100 μg/ml; Gibco), non-essential
amino acids (1%; PAA, Pasching, Austria), and sodium
pyruvate (1%; Sigma-Aldrich).
Monocytes were first incubated with dendrimer ABP
(10 μM) for one hour. They were then activated in the
presence of LPS from E. coli (20 ng/ml; Sigma-Aldrich)
and IFN-γ (250 U/ml) [28] for 38 hours for optimal
cytokine production. No cell death was observed in the
presence of dendrimer ABP, as expected from the study
by Poupot et al. [24], using flow cytometry Forward
Scatter and Side Scatter.
Generation and activation of monocyte-derived dendritic
cells (MoDC)
Immature MoDC were generated according to Sallusto
and Lanzavecchia [29]. Briefly, monocytes (0.8 × 106/ml)
were cultured in the presence of rIL-4 (50 ng/ml; Pepro-
Tech, Rocky Hill, NJ, USA) and rGM-CSF (100 ng/ml;
PeproTech) for six days. Culture media was complete 10%
FCS RPMI-1640. The phenotype was analyzed on FC-500
Coulter flow cytometer using the following antibodies anti
CD14-FITC (clone HCD14, BD Biosciences), CD11c-APC
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Biosciences), CD80-PE (clone 2D10, Bio Legend), CD83-
PerCP Cy5.5 (clone HB15e, Bio Legend), CD86-Alexa
Fluor 488 (clone IT2.2, Bio Legend) and corresponding
isotype controls. Data were analyzed using FlowJo
(Tree Star).
MoDC were cultured at the final concentration of
0.2 × 106/ml in complete 10% FCS RPMI-1640 media
and treated as Mo with regard to activation.
Production of cytokines
Cultured supernatants were collected and kept at -80°C
until analysis. Concentrations of IL-1β, IL-6, IL-10, IL-12
and TNFα were determined simultaneously using Cytomet-
ric Bead Array (Human Inflammatory Cytokine Kit, BD
Biosciences). Data acquisition was performed on a FACSCa-
libur (BD Biosciences) and analysis was performed using
FCAPArray v3 (Soft Flow). IL-23 was quantitated by ELISA
(Ready-SET-Go, eBioscience, San Diego, CA, USA) on a
Varioskan Flash (Thermo Scientific) spectrophotometer and
analyzed using the SkanIt™ (Thermo Scientific) program.
Statistical analysis
Statistical analyses were performed using Stata 12
(Statacorp LP). A bilateral paired Student’s t test wasFigure 1 Structure of dendrimer azabisphosphonate (mw = 5,820 da)performed when variables followed a Gaussian distribu-
tion (Shapiro-Wilk test). A paired rank Wilcoxon test
was used when applicable. Statistically, P <0.05 was con-
sidered as significant with 95% interval confidence.
Box plots (Figures 2 and 3) represent the 25th and 75th
percentiles (interquartile range, IQR). The ends of the
whiskers are the lowest and highest values, respectively.
When data did not follow normal distribution (Figure 4C)
SD or SEM could not be calculated. Bars represent the 75th
percentile.
Results
Actions of dendrimer ABP on pro-inflammatory cytokine
production by activated monocytes
The structure of dendrimer ABP (mw = 5,820 Da) is
shown in Figure 1 [24-26]. We evaluated the secretion of
TNFα, IL-1β, IL-6, IL-23 and IL-12 by monocytes from 12
healthy blood donors in 12 independent experiments.
Monocytes were pre-incubated in the presence or the ab-
sence of dendrimer ABP, and then activated by IFN-γ, LPS
and the association of LPS + IFN-γ, which is known to in-
duce a typical M1 phenotype [5]. Data are presented as
box plots in Figure 2 and in Table 1.
IFN-γ alone was not able to induce any studied cyto-
kine. Dendrimer ABP alone induced only a modest and.
Figure 2 Actions of dendrimer ABP on cytokine production by monocytes. TNFα, IL-1β, IL-6, IL-23, IL-12 and IL-10 were measured in the
culture supernatant of activated Mo from 12 donors. Data are presented as box plots. Activation was performed, as indicated, in the presence or
in the absence of dendrimer ABP. *P < 0.05; **P = 0.0005. ABP, aza-bis-phosphonate; IL, interleukin; Mo, monocytes; TNF, tumor necrosis factor.
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alone was sufficient to induce significant secretion of
TNFα , IL-1β and IL-6 by monocytes, but the associationLPS + IFN-γ was required to obtain higher production of
TNFα. IL-12 secretion was obtained only with the com-
bination of LPS + IFNγ, as expected from references
Figure 3 Actions of dendrimer ABP on cytokine production by MoDC. TNFα, IL-6, IL-23, IL-12 and IL-10 were measured in the culture
supernatant of activated MoDC from 11 donors. Data are presented as box plots. Activation was performed, as indicated, in the presence or in
the absence of dendrimer ABP. *P <0.05; **P <0.005. ABP, aza-bis-phosphonate; IL, interleukin; MoDC, monocyte derived dendritic cells; TNF, tumor
necrosis factor.
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Figure 4 Dendrimer ABP favors the IL-10 over IL-12 production in MoDC. The ratio of IL-12 to IL-10 production in the presence or in the
absence of ABP and LPS + IFN-γ +/− dendrimer ABP was calculated for Mo (A) and MoDC (B). When IL-10 levels were not detectable, detection
limit (5 pg/mL) was chosen as the denominator of the ratio. ABP, aza-bis-phosphonate; IFN-γ, interferon-gamma; IL, interleukin; LPS,
lipopolysaccharides; Mo, monocytes; MoDC, monocyte derived dendritic cells.
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different samples.
Dendrimer ABP at 10 μM induced a profound inhib-
ition of the production of TNFα (P = 0.0005) but also a
significant decrease of the secretion of IL-1β (P =
0.0186). On the opposite side, we observed a slight but
non-significant increase of IL-6 under the action of den-
drimer ABP after stimulation of monocytes by LPS and
by LPS + IFN-γ. IL-12 production was completely inhib-
ited by dendrimer ABP (P = 0.0159).
IL-23 production is mostly due to monocytes and DC
activated by danger signals, such as those provided by
TLRs [32]. Due to the importance of Th17 in arthritis,
IL-23 production was investigated. Secretion of IL-23 by
monocytes was induced in eight independent experi-
ments (Figure 2 and Table 1). Stimulation with LPS and
with LPS + IFN-γ induced IL-23 secretion. In bothTable 1 Summary of cytokine secretion by Mo and MoDC
Cytokines (pg/ml) Control; median (IQR) LPS + IFN-γ; m
Mo IL-12 0 (0; 0) 1 (0; 10)
Mo IL-10 0 (0; 5) 205 (110; 340)
Mo TNFα 0 (0; 6) 617 (302; 912)
Mo IL-1β 0 (0; 4) 448 (232; 953)
Mo IL-6 175 (57; 403) 10,059 (5,074; 1
Mo IL-23 115 (99; 181) 277 (188; 521)
MoDC IL-12 0 (0; 0) 45 (9; 166)
MoDC IL-10 0 (0; 0) 117 (53; 176)
MoDC TNFα 0 (0; 5) 458 (374; 786)
MoDC IL-1β 0 (0; 0) 0 (0; 0)
MoDC IL-6 13 (0; 29) 10,255 (7,262, 1
MoDC IL-23 130 (41; 152) 172 (104; 386)
Cytokines were measured in the supernatant of Mo and MoDC cultures. Concentrat
with LPS + IFN-γ with or without prior incubation with dendrimer ABP. Results are from
IFN-γ, interferon-gamma; IL, interleukin; IQR, interquartile range; LPS, lipopolysaccharidcases, pre-incubation with dendrimer ABP induced a
significantly lower production (respectively, P = 0.0431
and P = 0.0360). Stimulation by IFN-γ alone did not in-
duce IL-23 production above control. Dendrimer alone
did not induce IL-23 secretion.
Actions of dendrimer ABP on pro-inflammatory cytokine
production by MoDC
Cytokine production by activated MoDC in 11 donors
was measured in the same conditions as with monocytes
(Figure 3) but IL-1β production was never observed,
whatever the conditions (Table 1). LPS alone induced
significant production of TNFα and IL-6. Dendrimer
alone was never able to induce the secretion of the dif-
ferent cytokines. Again, dendrimer ABP has a clear-cut
effect on TNFα, decreasing the production induced by
LPS + IFN-γ (P = 0.0033).edian (IQR) LPS + IFN-γ + ABP; median (IQR) P
0 (0; 0) 0.0159
328 (206; 369) ns
147 (82: 195) 0.0005
261 (155; 688) 0.0186
3,251) 11,682 (7,537; 17,425) ns
184 (137; 244) 0.036
0 (0; 5) 0.0038
228 (157; 260) 0.001
241 (145, 481) 0.0033
0 (0, 8) ns
2,864) 8,131 (5,160; 11,310) ns
134 (93; 249) ns
ions were measured in the absence of stimulation (control) and after activation
12 (Mo) and 11 (MoDC) blood donors, respectively. ABP, aza-bis-phosphonate;
e; Mo, monocytes; MoDC, monocyte derived dendritic cells.
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IL-23 production. However, this production was not
significantly diminished by dendrimer ABP. As we ob-
served with monocytes, MoDC produced IL-12 after
stimulation with LPS and IFN-γ, with a heterogeneous
response, and this production was totally inhibited by
dendrimer ABP.
Stimulation by LPS or LPS + IFN-γ induced a signifi-
cant IL-6 production. However, no significant decrease
of IL-6 was observed in the presence of dendrimer ABP.Dendrimer ABP favors IL-10 over IL-12 production in
MoDC
In DC, the production of IL-10 is characteristic of tol-
erogenic DC which possess an immunomodulatory anti-
inflammatory activity. We have analyzed the secretion of
both cytokines in MoDC from 11 blood donors, in 11
independent experiments (Figure 5 and Table 1). In ac-
cordance with the literature, the level of IL-10 produc-
tion by MoDC was weakest in the presence of IFN-γ,
which is known to inhibit IL-10 [33]. The effect of
dendrimer was different according to the mode of cell
activation. In the absence of IFN-γ (LPS alone) the pro-
duction of IL-10 by MoDC was significantly diminished
(P = 0.0135). However, in the LPS + IFN-γ stimulation,
IL-10 production was down-regulated by IFN-γ com-
pared to LPS alone. Dendrimer ABP prevented down-
regulation of IL-10 induced in the presence of IFN-γ
during TLR4 stimulation (P = 0.001).
Similar to Mo, IL-12 production was obtained only in
the presence of LPS + IFNγ; the level of IL-12 was
significantly lower in the presence of dendrimer ABP.
The resulting IL-12:IL-10 ratio was significantly de-
creased in MoDC stimulated by LPS + IFN-γ and pre-
treated by dendrimer ABP (P = 0.0051) (Figure 4B). This
is strongly in favor of an anti-inflammatory activity.
In monocytes, a decrease of the IL-12:IL-10 ratio in
the presence of dendrimer was observed but did not
reach statistical significance although donors with the
highest initial IL-12:IL-10 ratios were the ones which
were the most affected by dendrimer ABP (Figure 4A).Dendrimer ABP affects the phenotype of TLR4-activated
MoDC
In addition to the TCR stimulation, two other signals
are indispensable for the activation of T lymphocytes:
engagement of co-stimulation molecules and cytokine
signaling. We thus have looked at the expression of
CD80 and CD86 by MoDC in flow cytometry ex-
periments. A decrease of CD1a and an increase of
CD83 were also examined as markers of maturation.
Phenotype of MoDC was controlled and found to
be CD14-, CD11c+, CD1a+, CD80low and CD86low(Figure 5A). The maturation phenotype of MoDC in the
presence of LPS + IFN-γ was assessed. Figure 5 shows
the classical maturation phenotype obtained from nine
donors in nine independent experiments (decrease of
CD1a, induction of CD83, CD80, CD86). CD80 and
CD86 expression was significantly lower in the presence
of dendrimer ABP (P <0.05) (Figure 5B, C). The expres-
sion of CD83 and CD1a was not altered by dendrimer
ABP. Thus, co-stimulation may be diminished in DC in
the presence of the immunomodulatory agent dendri-
mer ABP.
Discussion
In this current work, we have studied how ABP dendri-
mer can orientate Mo and MoDC toward phenotypes
capable of fighting classical pro-inflammatory stimulus
mediated by LPS and IFN-γ. We showed that dendrimer
ABP displays an anti-inflammatory activity by favoring
the M2 phenotype and by preventing TNFα and IL-23
production by Mo in the context of pro-inflammatory
stimulus. In MoDC, dendrimer ABP induced a tolero-
genic phenotype by favoring the secretion of IL-10 and
decreasing that of IL-12 and TNFα. Reduced expression
of CD80 and CD86 was also observed. Our data suggest
an immunomodulatory role of dendrimer ABP on both
Mo and MoDC. This may be of importance in breaking
the vicious circle of inflammation in the treatment of
arthritis.
Activated monocytes/macrophages are the main pro-
ducers of TNFα and IL-1β in the rheumatoid synovium.
The decrease of TNFα production by Mo and MoDC is
of importance with regard to RA treatment. On the one
hand, TNFα is a key mediator of synovial inflammation
and bone erosion [4,34]. On the other hand, it induces
the production of IL-1β, which is also responsible of
bone loss [35]. Whatever the mechanism, by a direct ef-
fect on IL-1β production or an indirect action through
the inhibition of TNFα, dendrimer ABP induced a de-
crease of IL-1β production in Mo.
In Mo and MoDC put in the presence of LPS + IFN-γ,
dendrimer ABP also decreased the production of IL-12
and increased IL-10, although the IL-12:IL-10 ratio was
significantly decreased only in MoDC. The decrease of
the IL-12:IL-10 ratio may also be in part responsible for
the decrease of CD80 and CD86 expression in MoDC.
In Mo, IL-12:IL-10 ratios were much lower than in
MoDC and may have been difficult to modulate. Indeed,
only blood donors with the highest IL-12:IL-10 ratio in
Mo showed a decrease after ABP treatment. Thus, an
alternative activation of Mo and MoDC is induced by
dendrimer ABP. This is in accordance with previous
publications on mRNA expression in Mo [26].
IL-10 is an anti-inflammatory cytokine which induces,
among others, regulatory T cells Tr1 [36] and, in DC,
Figure 5 Modulation of MoDC maturation by dendrimer ABP. A. the phenotype of immature MoDC was determined by flow cytometry.
Expression of CD14, CD1a, CD11c, CD83, CD80 and CD86 was evaluated after six days of differentiation in the presence of IL-4 and granulocyte-
macrophage colony-stimulating factor (GM-CSF). These results are representative of nine donors. B. Phenotype of mature MoDC was determined
by flow cytometry. Markers of MoDC were evaluated after incubation for 38 hours in the presence or in the absence of dendrimer ABP and
LPS + IFN-γ. The phenotype of non-manipulated, immature MoDC is shown as the control. These results are representative of nine donors. Mean
Fluorescence Intensity (MFI) differences between staining and isotype control are shown. C. Variation of expression of MoDC maturation markers
CD1a, CD83, CD80 and CD86. MFI was used to measure the level of expression of markers. Data are presented as the relative percentage of
expression, as compared to controls obtained in the absence of stimulation (100%). Bars correspond to the 75th percentile (IQR). Data are from
nine donors. *P <0.05. ABP, aza-bis-phosphonate; IFN-γ, interferon-gamma; IQR, interquartile range; LPS, lipopolysaccharides; MoDC, monocyte
derived dendritic cells.
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of maturation, of antigen presentation and of pro-
inflammatory cytokines production [33]. There is a com-
petition between intracellular signaling of IL-10 and
IFN-γ. IL-10 has been shown to inhibit STAT1 signaling
and the transcription of genes of the “IFN-γ signature”.
On the opposite side, IFN-γ inhibits the ERK- and p38-dependent production of IL-10 by blocking the STAT3
signaling [27,37]. IL-10 production by MoDC was in-
creased by dendrimer ABP in the context of LPS + IFN-
γ signaling. We may thus hypothesize that dendrimer
ABP decreases the inhibitory action of IFN-γ on IL-10
production. This is particularly illustrated by the fact
that, in MoDC, ABP alone (or in the presence of LPS)
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absence of IFN-γ. If the orientation of dendrimer ABP-
treated MoDC is tolerogenic, this should have a benefi-
cial effect with regard to anti-RA therapeutic objectives.
Thus, our current data are more informative with regard
to MoDC, which are highly relevant cells in RA [38].
This trend towards IL-10 production has already been
observed in arthritic mice treated with dendrimer ABP
[25] and in a rat model of uveitis [39]. We make the hy-
pothesis that dendrimer ABP possesses stronger immu-
nomodulatory properties when IFN-γ stimulation is
engaged. This is supported by the observation of dendri-
mer ABP effect on IL-1β in Mo and IL-6 in MoDC in
the LPS + IFN-γ, but not in the context of LPS alone.
The mechanism of action of dendrimer ABP on the
JAK-STAT pathway remains to be investigated.
DC are most important in antigen presentation and
orientation of the T cell immune response. Dendrimer
ABP may participate in the immunomodulation as well,
by acting on co-stimulation (decrease of CD80 and
CD86) and decrease of cytokine secretion. Future experi-
ments will determine whether the decrease of CD80 and
CD86 and the decrease of IL-12 production have an im-
pact on the T helper cell compartment.
The role of IFN-γ in RA is controversial. On the one
hand, IFN-γ activates Mo/macrophages in the synovium
[1]. On the other hand, mice deficient in IFN-γ receptors
have accelerated collagen-induced arthritis [40] and IFN-γ
inhibits the development of osteoclasts [4] and of Th17
cells [41], which are major players in arthritis. In this
current study, we have used IFN-γ along with the TLR4
agonist LPS as classical tools to activate Mo to M1
polarization and induce cytokine production. Whether
this reflects precisely the activation in vivo in RA is be-
yond the scope of our study.
Most of the current treatments for RA are aimed at
neutralizing inflammatory cytokines. Blocking TNFα was
shown in early publications to result in the inhibition of
IL-1β, IL-6 and IL-8 production, thus putting TNFα at
the center stage of inflammatory cytokine regulation and
providing a rationale for the use of anti-TNF reagents. It
is thus of interest that inhibition of TNFα production
was a prominent feature of the effect of dendrimer ABP
on both Mo and MoDC, although it was not followed by
inhibition of IL-1β in MoDC and by inhibition of IL-6.
It is of note that our setting allows for the analysis of
isolated populations. However, in our previous study, the
resulting effect of dendrimer ABP action in arthritic
mice was a dramatic decrease of both IL-1β and IL-6
[25], suggesting a strong in vivo capability to decrease
inflammatory cytokines involved in arthritis. In addition,
our current work shows that IL-12 production was de-
creased in Mo and MoDC. However, IL-23 was signifi-
cantly decreased only in Mo.Conclusion
We have added to the understanding of mechanisms of ac-
tion of a potential therapeutic agent dendrimer ABP. We
have confirmed that dendrimer ABP orientates Mo to-
wards an M2 phenotype and shown that orientation of
MoDC is towards a tolerogenic phenotype. Our data are in
accordance with previous observations from our laboratory
showing immunomodulatory and anti-osteoclastic effects
[25,26]. Our data add further arguments for dendrimer
ABP as a potential therapeutic agent ofor RA.
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